 BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 GLOBE NEWSWIRE -- Talaris Therapeutics, Inc. Nasdaq: TALS, a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences: 